This issue brings together two studies: a new way to deliver treatment inside cells, and how a gene that determines skin and hair color connects to how fast Parkinson’s progresses. One is a delivery-technology study; the other is a large cohort study of a common gene variant and progression speed.
Antibodies that could not reach the inside of cells were delivered there using nanoparticles
🔍 How this came about
Researchers at Tel Aviv University, Cornell University, and the Technion — Israel Institute of Technology developed a lipid nanoparticle (LNP)A tiny carrier made of a fat-like shell that transports drugs into cells.Learn more technology for delivering antibodies inside cells. Antibodies are powerful at targeting molecules on the cell surface or outside the cell, but they cannot cross the cell membrane, so they have largely been unusable against targets located inside cells — even though a large share of disease-related proteins sit inside cells.
The team solved this by temporarily wrapping antibodies with a synthetic molecule called SL4. The masked antibodies loaded far more efficiently into nanoparticles, and once inside the cell they regained their original structure and function. Applying this to an antibody targeting alpha-synucleinA protein normally present in the brain. In Parkinson's it clumps abnormally and builds up inside dopamine neurons.Learn more and giving it systemically in a Parkinson’s animal model significantly reduced pathological alpha-synuclein clumps. The same approach, applied to an inflammation-related antibody in an acute lung injury model, reduced inflammation markers and improved lung tissue.
✅ If you live with Parkinson’s
This is not a treatment available for people — it is animal-model research validating the delivery technology itself. Antibody therapies are already widely used for cancer and autoimmune disease, but treatments aimed at targets inside cells need a delivery technology like this one before they can move into human trials.
🙋 If you are a care partner
When you come across a phrase like “a treatment targeting alpha-synuclein,” it helps to check which stage it is at. Animal-model research, early human trials, and large clinical trials are different stages, and this research is currently at the earliest of those.
MC1RMelanocortin 1 receptor, a gene best known for determining skin and hair pigmentation. This study found it also helps regulate oxidative stress in substantia nigra neurons.Learn more variant carriers showed up to 63% faster motor decline
🔍 How this came about
Researchers at Massachusetts General Hospital (Harvard Medical School) analyzed data from 809 participants in the Parkinson’s Progression Markers Initiative (PPMI) and a separate group of 587 clinical trial participants — 1,396 people in total — to examine how a loss-of-function MC1R variant relates to the speed of motor decline. MC1R is best known as the gene that determines skin and hair pigmentation, and this variant is carried by more than 60% of people of European descent.
The analysis found that MC1R variant carriers showed 30% faster motor decline on the UPDRSA scale used to assess motor and non-motor symptoms of Parkinson's and their effect on daily life.Learn more motor score than non-carriers, and in a separate replication cohort that gap widened to 50%. Among carriers who inherited the variant from both parents, progression was up to 63% faster. Even among participants not yet diagnosed with Parkinson’s, carriers were more than four times as likely to go on to develop the disease.
✅ If you live with Parkinson’s
The MC1R variant is common and carried by a majority of people of European descent. The researchers say it could be used to identify a large subgroup of faster-progressing people with Parkinson’s through a simple genetic test, and could become a target for future drug development. That said, this research was conducted mainly in populations of European descent, and whether the same proportions apply here has not been confirmed.
🙋 If you are a care partner
If a genetic test result comes up, talk with your care team about what it means and what, if anything, should change. The test used in this research is not yet a routine clinical test, and interpreting results requires considering factors such as population background and interactions with other genes.
What you can do now
These two studies sit at different stages — one tested a delivery technology in an animal model, and the other confirmed how an already-existing gene variant plays out in real people. What you can do right now is not to seek out a new test on your own, but to keep track of how symptoms are changing and share that with your care team at the next visit.
This article is ParkinON’s plain-language summary of recently published research and news. It is not a substitute for medical diagnosis or treatment, and does not reflect approval or availability status in any specific country. Please talk to your care team about any questions regarding new treatments.